General
Preferred name
azelaprag
Synonyms
AMG 986 ()
P&D ID
PD086496
CAS
2049980-18-7
Tags
drug candidate
available
Drug indication
Heart failure
Drug Status
investigational
Max Phase
1.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
AMG 986 is an apelin receptor agonist that is claimed in Amgen's patent WO2016187308A1 (as example 263) . The chemical structure is identical to that submitted to the WHO for the INN azelaprag. Apelin receptor agonists are being pursued for their clinical inotropic potential in the treatment of heart failure.
PRICE
422
DESCRIPTION
Azelaprag (AMG 986) is an apelin receptor agonist that is claimed in Amgen's patent WO2016187308A1 (as example 263) . The chemical structure is identical to that submitted to the WHO for the INN azelaprag. Apelin receptor agonists are being pursued for their clinical inotropic potential in the treatment of heart failure.
(GtoPdb)
DESCRIPTION
Azelaprag (AMG 986) is an effective small-molecule apelin receptor agonist. Azelaprag can be used to treat neurological diseases and cardiovascular diseases.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
7
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
12
Molecular Weight
523.2
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
1
Rotatable Bonds
9
Ring Count
4
Aromatic Ring Count
4
cLogP
3.69
TPSA
134.01
Fraction CSP3
0.32
Chiral centers
2.0
Largest ring
6.0
QED
0.35
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Apelin receptor
Apelin Receptor (APJ)
Pathway
GPCR/G protein
Source data
